Name : Mouse CD39/ENTPD1 Protein
Product Source :
Recombinant Mouse CD39/ENTPD1 Protein is expressed from HEK293 with His tag at the C-Terminus. It contains Thr38-Ile478.[Accession | P55772]
Molecular Weight :
The protein has a predicted MW of 50.72 kDa. Due to glycosylation, the protein migrates to 68-78 kDa based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE> 95% as determined by HPLC
Formulation :
Lyophilized from 0.22μm filtered solution in 20mM Tris-HCl, 150mM NaCl (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt.-80°C for 3-6 months after reconstitution.2-8°C for 2-7 days after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Mouse CD39 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. SEC-HPLC The purity of Mouse CD39 is greater than 95% as determined by SEC-HPLC. Bioactivity Data Measured by its ability to hydrolyze the 5′-phosphate groups from the substrate adenosine-5′-triphosphate (ATP). The specific activity is >18,000 pmol/min/µg.
Background :
CD39, also known as ENTPD1, belongs to the GDA1/CD39 NTPase family. It is expressed primarily on activated lymphoid cells and can also be detected in endothelial tissues.CD39 is involved in the processes of thromboregulation and vascular inflammation. The administration of soluble NTPDase-1 may have therapeutic applications for the treatment of some vascular and transplantation-associated diseases .
Synonyms :
NTPDase 1; Ecto-ATPDase 1; Ecto-ATPase 1; Ecto-apyrase; Entpd1; ADPase; ATPDase; NTPD1; NTPDase 1; NTPDase-1
References & Citations :
(1)Häusler SF, Del Barrio I M , Diessner J , et al. Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion.[J]. Am J Transl Res, 2014, 6(2):129-139.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
TNF-alpha/TNFSF2 Proteincustom synthesis
envelope glycoprotein gp160 ProteinFormulation
Popular categories:
IGF-I R/CD221
Influenza Non-structural Protein 1